In vitro and in situ effects of atorvastatin and ezetimibe on P-glycoprotein expression and function
DOI:
https://doi.org/10.3329/bjp.v11i4.27404Keywords:
Atorvastatin, Ezetimibe, Intestinal permeability, P-glycoproteinAbstract
P-glycoprotein (P-gp) is a membrane transporter responsible for the active efflux from the cell. Inhibition of the activity may lead to clinically significant drug-drug interactions. This study was performed to investigate the effects of atorvastatin and ezetimibe on the function and expression of P-gp. The in vitro rhodamine-123 (Rho123) efflux assay and Western blot in Caco-2 cells, and the in situ rat single-pass intestinal permeability model followed by high performance liquid chromatography were developed. Rho123 intracellular accumulation in 100 µM of atorvastatin- and ezetimibe-treated cells was significantly higher than that in control cells (p<0.05). P-gp expression was decreased by 100 µM atorvastatin and ezetimibe. Intestinal effective permeability of digoxin in the presence of atorvastatin (3 and 100 µM), ezetimibe (10 and 100 µM) was significantly increased (p<0.05). Both drugs inhibited P-gp activity in vitro and in situ. Atorvastatin and ezetimibe down-regulated the expression of P-gp in vitro.
Video Clip of Methodology:
Single-pass intestinal permeability: 17 min 26 sec Full Screen Alternative
Downloads
2
1 Read
1
References
Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev. 2012; 12: CD008226.
Ando A, Sasago S, Ohzone Y, Miyamoto Y. Drugdrug inter-actions of a novel ?-opioid receptor agonist, nalfurafine hydrochloride, involving the P-glycoprotein. Eur J Drug Metab Pharmacokinet. 2015; 2015.
Bandyopadhyay S, Katare OP, Singh B. Colloids and surfaces B. Optimized self-nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Biointerfaces 2012; 100: 50-61.
Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin co-administration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000; 40: 91-98.
Horwich TB, MacLellan WR. Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother. 2007; 8: 3061-68.
Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003; 42: 1141-60.
Li Y, Huang L, Zeng X, Zhong G, Ying M, Huang M, Bi H. Down-regulation of P-gp expression and function after mulberroside A treatment: Potential role of protein kinase C and NF-kappa B. Chem Biol Int. 2014; 213: 4450.
Lioudaki E, Ganotakis ES, Mikhailidis DP. Ezetimibe: More than a low density lipoprotein cholesterol lowering drug? An update after 4 years. Curr Vasc Pharmacol. 2011; 9: 62-86.
Mohammadzadeh R, Baradaran B, Valizadeh H, Yousefi B, Zakeri-Milani P. Reduced ABCB1 expression and activity in the presence of acrylic copolymers. Adv Pharm Bull. 2014; 4: 219-24.
OConnor M, Lee C, Ellens H, Bentz J. A novel application of t-statistics to objectively assess the quality of IC50 fits for P-glycoprotein and other transporters. Pharm Res Per. 2015; 3: e00078.
Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R, Wacke W, Cascorbi I, Kroemer HK, Weitschies W, Bergmann K, Siegmund W. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 pre-dicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006a; 79: 206-17.
Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. J Pharm Exp Ther. 2006b; 318: 1293-99.
Oswald S, Koll C, Siegmund W. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (_/_) mice. J Pharm Sci. 2007; 96: 3478-84.
Patel JR, Barve KH. Intestinal permeability of lamivudine using single pass intestinal perfusion. Indian J Pharm Sci. 2012; 74: 47881.
Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: Mechanism of action and clinical update. Vasc Health Risk Manag. 2012; 8: 41527.
Prasad N, Bhasker S. Characterization of intestinal transport of Vincristine in rats applying in situ single pass intestinal perfusion. Pharmacologia 2012; 3: 617-21.
Rodde MS, Divase GT, Devkar TB, Tekade AR. Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: In vitro, ex vivo, and in vivo studies. BioMed Res Int. 2014; 2014.
Suchy D, Labuzek K, Stadnicki, Okopieñ B. Ezetimibe: A new approach in hypercholesterolemia management. Pharmacol Reports. 2011; 63: 1335-48.
Valizadeh H, Mehtari M, Zakeri-Milani P. Evidence for enhanced intestinal absorption of digoxin by P-glycoprotein inhibi-tors. Trop J Pharm Res. 2012; 11: 939-45.
Vatsa R, Varanasib KVS, Arlab R, Veeraraghavanb S, Rajakb S, Murthya AN. Effect of multidose cilostazol on pharmaco-kinetic and lipid profile of atorvastatin in male Wistar rats. J Pharm Pharmacol. 2012; 64: 1638-45.
Wanga XD, Menga MX, Gaoa LB, Liua T, Xub Q, Zenga S. Permeation of astilbin and taxifolin in Caco-2 cell and their effects on the P-gp. Int J Pharm. 2009; 378: 1-8.
Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am College Cardiol. 2013; 61: 2495502.
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41: 343-70.
Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000; 17: 209-15.
Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, Barzegar S, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007; 10: 368-79.
Zastrea J, Jacksona J, Bajwaa M, Ligginsb R, Iqbala F, Burta H. Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block-polycaprolactone diblock copolymers. Eur J Pharm Biopharm. 2002; 54: 299309.
Zrieki A, Farinotti R, Buyse M. Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycol-protein up-regulation in vitro and in vivo. Eur J Pharm. 2010; 636: 18997.
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
